FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of treating cancer in a patient. Method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a combination comprising: (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulphinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2)-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one or a pharmaceutically acceptable salt thereof; and a checkpoint inhibitor selected from the group consisting of an anti-CTLA-4 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody.
EFFECT: use of the invention provides the effective treatment of cancer.
7 cl, 7 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| PYRIDINONE PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | 2007 |
|
RU2472782C2 |
| MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | 2014 |
|
RU2678830C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| PI-3 KINASE DOSAGE REGIME | 2013 |
|
RU2630975C2 |
| TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
| (R)-2-METHYL-PIPERAZINE DERIVATIVES AS MODULATORS OF CXCR3 RECEPTOR | 2016 |
|
RU2706232C2 |
| FGFR INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2745035C1 |
